The role and control of arginine levels in arginase 1 deficiency.
J Inherit Metab Dis
; 46(1): 3-14, 2023 01.
Article
in En
| MEDLINE
| ID: mdl-36175366
ABSTRACT
Arginase 1 Deficiency (ARG1-D) is a rare urea cycle disorder that results in persistent hyperargininemia and a distinct, progressive neurologic phenotype involving developmental delay, intellectual disability, and spasticity, predominantly affecting the lower limbs and leading to mobility impairment. Unlike the typical presentation of other urea cycle disorders, individuals with ARG1-D usually appear healthy at birth and hyperammonemia is comparatively less severe and less common. Clinical manifestations typically begin to develop in early childhood in association with high plasma arginine levels, with hyperargininemia (and not hyperammonemia) considered to be the primary driver of disease sequelae. Nearly five decades of clinical experience with ARG1-D and empirical studies in genetically manipulated models have generated a large body of evidence that, when considered in aggregate, implicates arginine directly in disease pathophysiology. Severe dietary protein restriction to minimize arginine intake and diversion of ammonia from the urea cycle are the mainstay of care. Although this approach does reduce plasma arginine and improve patients' cognitive and motor/mobility manifestations, it is inadequate to achieve and maintain sufficiently low arginine levels and prevent progression in the long term. This review presents a comprehensive discussion of the clinical and scientific literature, the effects and limitations of the current standard of care, and the authors' perspectives regarding the past, current, and future management of ARG1-D.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hyperargininemia
/
Hyperammonemia
/
Urea Cycle Disorders, Inborn
Limits:
Child, preschool
/
Humans
Language:
En
Journal:
J Inherit Metab Dis
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos